{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:06:55Z","timestamp":1791295615971,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T00:00:00Z","timestamp":1447632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T00:00:00Z","timestamp":1447632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1038\/nm.3995","type":"journal-article","created":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T11:37:52Z","timestamp":1447673872000},"page":"1473-1480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":152,"title":["Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition"],"prefix":"10.1038","volume":"21","author":[{"given":"Qiang","family":"Jeremy Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Goldenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Malinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka K","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J","family":"Breyfogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Koppikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Gurbuxani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mullally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Crispino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,16]]},"reference":[{"key":"BFnm3995_CR1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat, N. et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J. Clin. Oncol. 29, 392\u2013397 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnm3995_CR2","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2013-02-482232","volume":"121","author":"J Mascarenhas","year":"2013","unstructured":"Mascarenhas, J. & Hoffman, R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood 121, 4832\u20134837 (2013).","journal-title":"Blood"},{"key":"BFnm3995_CR3","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","volume":"110","author":"SO Ciurea","year":"2007","unstructured":"Ciurea, S.O. et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 110, 986\u2013993 (2007).","journal-title":"Blood"},{"key":"BFnm3995_CR4","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi, A.M. et al. Mutations and prognosis in primary myelofibrosis. Leukemia 27, 1861\u20131869 (2013).","journal-title":"Leukemia"},{"key":"BFnm3995_CR5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ajh.23169","volume":"87","author":"O Abdel-Wahab","year":"2012","unstructured":"Abdel-Wahab, O. et al. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am. J. Hematol. 87, 562\u2013568 (2012).","journal-title":"Am. J. Hematol."},{"key":"BFnm3995_CR6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40291-012-0006-3","volume":"16","author":"R Tibes","year":"2012","unstructured":"Tibes, R., Bogenberger, J.M., Benson, K.L. & Mesa, R.A. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. Mol. Diagn. Ther. 16, 269\u2013283 (2012).","journal-title":"Mol. Diagn. Ther."},{"key":"BFnm3995_CR7","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl, T. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 369, 2379\u20132390 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3995_CR8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia, J. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 369, 2391\u20132405 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3995_CR9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799\u2013807 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3995_CR10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787\u2013798 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3995_CR11","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","volume":"119","author":"A Tefferi","year":"2012","unstructured":"Tefferi, A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119, 2721\u20132730 (2012).","journal-title":"Blood"},{"key":"BFnm3995_CR12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/13543784.2013.774373","volume":"22","author":"CS Tam","year":"2013","unstructured":"Tam, C.S. & Verstovsek, S. Investigational Janus kinase inhibitors. Expert Opin. Investig. Drugs 22, 687\u2013699 (2013).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnm3995_CR13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/17474086.2013.827413","volume":"6","author":"C Harrison","year":"2013","unstructured":"Harrison, C. et al. Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev. Hematol. 6, 511\u2013523 (2013).","journal-title":"Expert Rev. Hematol."},{"key":"BFnm3995_CR14","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood.V90.11.4369","volume":"90","author":"JL Villeval","year":"1997","unstructured":"Villeval, J.L. et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90, 4369\u20134383 (1997).","journal-title":"Blood"},{"key":"BFnm3995_CR15","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1093\/emboj\/16.13.3965","volume":"16","author":"RA Shivdasani","year":"1997","unstructured":"Shivdasani, R.A., Fujiwara, Y., McDevitt, M.A. & Orkin, S.H. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 16, 3965\u20133973 (1997).","journal-title":"EMBO J."},{"key":"BFnm3995_CR16","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2002-06-1913","volume":"100","author":"AM Vannucchi","year":"2002","unstructured":"Vannucchi, A.M. et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1low mice). Blood 100, 1123\u20131132 (2002).","journal-title":"Blood"},{"key":"BFnm3995_CR17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cell.2012.06.032","volume":"150","author":"Q Wen","year":"2012","unstructured":"Wen, Q. et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 150, 575\u2013589 (2012).","journal-title":"Cell"},{"key":"BFnm3995_CR18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2014.14","volume":"34","author":"B Goldenson","year":"2015","unstructured":"Goldenson, B. & Crispino, J.D. The Aurora kinases in cell cycle and leukemia. Oncogene 34, 537\u2013545 (2015).","journal-title":"Oncogene"},{"key":"BFnm3995_CR19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine, R.L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387\u2013397 (2005).","journal-title":"Cancer Cell"},{"key":"BFnm3995_CR20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood-2005-07-2740","volume":"107","author":"DL Stachura","year":"2006","unstructured":"Stachura, D.L., Chou, S.T. & Weiss, M.J. Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. Blood 107, 87\u201397 (2006).","journal-title":"Blood"},{"key":"BFnm3995_CR21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-9440(10)62056-1","volume":"167","author":"AM Vannucchi","year":"2005","unstructured":"Vannucchi, A.M. et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am. J. Pathol. 167, 849\u2013858 (2005).","journal-title":"Am. J. Pathol."},{"key":"BFnm3995_CR22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/sj.leu.2401608","volume":"14","author":"K Uozumi","year":"2000","unstructured":"Uozumi, K. et al. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia 14, 142\u2013152 (2000).","journal-title":"Leukemia"},{"key":"BFnm3995_CR23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally, A. et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17, 584\u2013596 (2010).","journal-title":"Cancer Cell"},{"key":"BFnm3995_CR24","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1182\/blood-2014-12-615401","volume":"125","author":"B Goldenson","year":"2015","unstructured":"Goldenson, B., Kirsammer, G., Stankiewicz, M.J., Wen, Q.J. & Crispino, J.D. Aurora kinase A is required for hematopoiesis but is dispensable for mouse megakaryocyte endomitosis and differentiation. Blood 125, 2141\u20132150 (2015).","journal-title":"Blood"},{"key":"BFnm3995_CR25","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood-2009-11-251074","volume":"116","author":"J den Hollander","year":"2010","unstructured":"den Hollander, J. et al. Aurora kinases A and B are upregulated by Myc and are essential for maintenance of the malignant state. Blood 116, 1498\u20131505 (2010).","journal-title":"Blood"},{"key":"BFnm3995_CR26","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2007-07-102186","volume":"111","author":"G Wernig","year":"2008","unstructured":"Wernig, G. et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 111, 3751\u20133759 (2008).","journal-title":"Blood"},{"key":"BFnm3995_CR27","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.febslet.2011.04.068","volume":"585","author":"K Sumi","year":"2011","unstructured":"Sumi, K., Tago, K., Kasahara, T. & Funakoshi-Tago, M. Aurora kinase A critically contributes to the resistance to anticancer drug cisplatin in JAK2V617F mutant\u2013induced transformed cells. FEBS Lett. 585, 1884\u20131890 (2011).","journal-title":"FEBS Lett."},{"key":"BFnm3995_CR28","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","volume":"115","author":"P Koppikar","year":"2010","unstructured":"Koppikar, P. et al. Efficacy of the JAK2 inhibitor INCB16562 in a mouse model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 115, 2919\u20132927 (2010).","journal-title":"Blood"},{"key":"BFnm3995_CR29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","volume":"13","author":"G Wernig","year":"2008","unstructured":"Wernig, G. et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a mouse model of JAK2V617F-induced polycythemia vera. Cancer Cell 13, 311\u2013320 (2008).","journal-title":"Cancer Cell"},{"key":"BFnm3995_CR30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1128\/MCB.01062-08","volume":"29","author":"DO Cowley","year":"2009","unstructured":"Cowley, D.O. et al. Aurora A kinase is essential for bipolar spindle formation and early development. Mol. Cell. Biol. 29, 1059\u20131071 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm3995_CR31","first-page":"427","volume":"154","author":"H Castro-Malaspina","year":"1984","unstructured":"Castro-Malaspina, H. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. Prog. Clin. Biol. Res. 154, 427\u2013454 (1984).","journal-title":"Prog. Clin. Biol. Res."},{"key":"BFnm3995_CR32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0369-8114(00)00021-3","volume":"49","author":"MC Le Bousse-Kerdil\u00e8s","year":"2001","unstructured":"Le Bousse-Kerdil\u00e8s, M.C. & Martyre, M. C. & French INSERM Research Network on Idiopathic Myeolofibrosis. Involvement of the fibrogenic cytokines, TGF-\u03b2 and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol. Biol. (Paris) 49, 153\u2013157 (2001).","journal-title":"Pathol. Biol. (Paris)"},{"key":"BFnm3995_CR33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.1991.tb07952.x","volume":"77","author":"MC Martyr\u00e9","year":"1991","unstructured":"Martyr\u00e9, M.C., Magdelenat, H., Bryckaert, M.C., Laine-Bidron, C. & Calvo, F. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-\u03b2 in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol. 77, 80\u201386 (1991).","journal-title":"Br. J. Haematol."},{"key":"BFnm3995_CR34","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2353\/ajpath.2008.071030","volume":"172","author":"O Bock","year":"2008","unstructured":"Bock, O. et al. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. Am. J. Pathol. 172, 951\u2013960 (2008).","journal-title":"Am. J. Pathol."},{"key":"BFnm3995_CR35","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1096\/fj.11-193078","volume":"26","author":"G Hoermann","year":"2012","unstructured":"Hoermann, G. et al. Identification of oncostatin M as a JAK2V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB J. 26, 894\u2013906 (2012).","journal-title":"FASEB J."},{"key":"BFnm3995_CR36","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","volume":"100","author":"H Chagraoui","year":"2002","unstructured":"Chagraoui, H. et al. Prominent role of TGF-\u03b21 in thrombopoietin-induced myelofibrosis in mice. Blood 100, 3495\u20133503 (2002).","journal-title":"Blood"},{"key":"BFnm3995_CR37","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm.3707","volume":"20","author":"I Bruns","year":"2014","unstructured":"Bruns, I. et al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat. Med. 20, 1315\u20131320 (2014).","journal-title":"Nat. Med."},{"key":"BFnm3995_CR38","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm.3706","volume":"20","author":"MPJ Zhao","year":"2014","unstructured":"Zhao, M.P.J. et al. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat. Med. 20, 1321\u20131326 (2014).","journal-title":"Nat. Med."},{"key":"BFnm3995_CR39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","volume":"13","author":"K Schepers","year":"2013","unstructured":"Schepers, K. et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13, 285\u2013299 (2013).","journal-title":"Cell Stem Cell"},{"key":"BFnm3995_CR40","doi-asserted-by":"crossref","first-page":"ra54","DOI":"10.1126\/scisignal.2003910","volume":"6","author":"CA Dodson","year":"2013","unstructured":"Dodson, C.A., Yeoh, S., Haq, T. & Bayliss, R. A kinetic test characterizes kinase intramolecular and intermolecular autophosphorylation mechanisms. Sci. Signal. 6, ra54 (2013).","journal-title":"Sci. Signal."},{"key":"BFnm3995_CR41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T.C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27\u201355 (1984).","journal-title":"Adv. Enzyme Regul."},{"key":"BFnm3995_CR42","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1126\/science.7660125","volume":"269","author":"R K\u00fchn","year":"1995","unstructured":"K\u00fchn, R., Schwenk, F., Aguet, M. & Rajewsky, K. Inducible gene targeting in mice. Science 269, 1427\u20131429 (1995).","journal-title":"Science"},{"key":"BFnm3995_CR43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/immu.200310005","volume":"33","author":"J de Boer","year":"2003","unstructured":"de Boer, J. et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur. J. Immunol. 33, 314\u2013325 (2003).","journal-title":"Eur. J. Immunol."},{"key":"BFnm3995_CR44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/35004599","volume":"404","author":"K Akashi","year":"2000","unstructured":"Akashi, K., Traver, D., Miyamoto, T. & Weissman, I.L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193\u2013197 (2000).","journal-title":"Nature"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.3995.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3995","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3995.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:54:12Z","timestamp":1684436052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.3995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,16]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["BFnm3995"],"URL":"https:\/\/doi.org\/10.1038\/nm.3995","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725939047.793515319","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,16]]},"assertion":[{"value":"7 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}